NEW YORK (GenomeWeb News) – Investment bank JPMorgan has initiated coverage of Illumina with an “Overweight” rating on the firm’s stock.
JPMorgan analyst Tycho Peterson said in a lengthy research note published today that Illumina is “one of the best positioned [companies] to capitalize on a growing market for genetic analysis tools, including products for genotyping gene expression, next-generation DNA sequencing, molecular diagnostics, and for the applied and consumer markets.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.